GLA
CUE icon

Good Life Advisors’s Cue Biopharma CUE Stock Holding History

Good Life Advisors’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,333
Closed -$436K – 498
2024
Q4 		$436K Hold
13,333
– – 0.03% 316
2024
Q3 		$303K Buy
13,333
+2,500
+23% +$54.1K 0.02% 465
2024
Q2 		$403K Buy
10,833
+7,500
+225% +$371K 0.03% 305
2024
Q1 		$189K Hold
3,333
– – 0.02% 435
2023
Q4 		$264K Sell
3,333
-400
-11% -$28.6K 0.03% 354
2023
Q3 		$258K Buy
3,733
+1,200
+47% +$117K 0.03% 343
2023
Q2 		$277K Hold
2,533
– – 0.03% 323
2023
Q1 		$271K Buy
2,533
+33
+1% +$3.15K 0.03% 314
2022
Q4 		$214K Buy
2,500
+600
+32% +$54.9K 0.03% 320
2022
Q3 		$127K Hold
1,900
– – 0.02% 329
2022
Q2 		$142K Buy
+1,900
New +$222K 0.02% 339

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.97B AUM 32.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Good Life Advisors's CUE Position: Q1 2025 in Review

Good Life Advisors sold out of Cue Biopharma (CUE) in Q1 2025, closing a stake of 13,333 shares — an estimated $436K sold.

Good Life Advisors first reported a position in CUE in Q2 2022 and held it in 11 quarters. The position peaked at $436K in Q4 2024. 49 funds tracked by Wall St. Rank hold CUE as of Q1 2025.

  • Good Life Advisors reported no remaining Cue Biopharma position as of Q1 2025 after selling out during the quarter.
  • Good Life Advisors sold 13,333 Cue Biopharma shares in Q1 2025, an estimated $436K.
  • Good Life Advisors first reported a position in Cue Biopharma in Q2 2022 and held it in 11 quarters.
  • Good Life Advisors's Cue Biopharma position peaked at $436K in Q4 2024.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2025.

Based on Good Life Advisors's 13F filing for Q1 2025, filed 17 Apr 2025.